- Home
- Clinical Care
- Diabetes and kidney health: the checks that can find trouble early
Diabetes and kidney health: the checks that can find trouble early
GRAYMEDY DIABETES GUIDE · November 15, 2026
Kidney disease can develop without obvious symptoms. For a person living with diabetes, routine checks can reveal changes before they feel unwell and create an opportunity to discuss treatment.
Two different tests
A blood test estimates how well the kidneys filter blood, usually reported as estimated glomerular filtration rate (eGFR). A urine test checks for albumin, a protein that can leak into urine when the kidney filters are damaged. The two results provide different information; one does not make the other unnecessary.
An abnormal result does not automatically establish permanent kidney disease. A clinician interprets it alongside previous results and may repeat testing because illness and other factors can affect a measurement. Ask what the numbers mean for you and when they should be checked again.
Care beyond a test result
High blood glucose over time can damage kidney blood vessels; high blood pressure increases risk as well. Managing glucose and blood pressure, using appropriate medicines and attending follow-up can help protect kidney health. The right plan depends on kidney function, other conditions, medicines and individual circumstances.
Some diabetes medicines can have kidney or heart benefits for certain patients, while some treatments require extra caution or dose adjustment when kidney function changes. A clinician or pharmacist can review the whole medicine list, including over-the-counter pain medicines and supplements. Do not stop or change a prescription without advice.
Make the next visit useful
Ask whether both urine albumin and eGFR have been checked, what your blood pressure goal is, and which changes require follow-up. Tell the team about difficulties obtaining medicines or attending appointments. Seek prompt medical advice for concerning new symptoms rather than waiting for a routine test.
Source: NIDDK, Diabetic Kidney Disease. General information, not personal medical advice. Photo: RDNE Stock project / Pexels; illustrative.
Clinical Care
View moreWhen someone has an infection, choosing the right treatment can depend on more than identifying symptoms. A laboratory test can help clinicians find the cause and, in some circumstances, determine which medicines are likely to work. On 16 November, the World Health Organization published an essential package of diagnostic tests for bacterial and fungal infections and antimicrobial resistance. It sets out a prioritized range of tests for different levels of care, from primary care to referral hospitals. The package includes rapid tests, microscopy, culture, serology and molecular methods. Some tests help identify an organism; antimicrobial susceptibility testing can help show whether a bacterium or fungus is likely to respond to particular medicines. Which test is appropriate depends on the patient, the suspected infection and the resources available. Testing also has limits. Results must be interpreted alongside the clinical picture, and not every infection requires the same test. For a seriously ill patient, a clinician may need to start treatment before results are available and adjust it later when more information arrives. WHO says access to reliable diagnostics remains uneven, particularly in low- and middle-income countries. Its package is intended to help health systems plan services and improve access to timely, quality-assured testing. During World AMR Awareness Week, the message is straightforward: better diagnosis can support better treatment decisions, while helping health systems track drug resistance. Patients should follow their clinician’s advice and ask what a test result means for their care. Source: World Health Organization, 16 November 2026.
Taking blood pressure at home: small steps that make readings more useful
Bone density and fracture risk: when to ask about a DXA scan
Diabetes and kidney health: the checks that can find trouble early
Some mornings, tiredness has an obvious explanation: a late night, a stressful week, or a child who kept waking up. But when exhaustion continues even after you have tried to rest, it can be difficult to know whether to wait it out or ask for help. Fatigue is a symptom, not a diagnosis. The most useful question is often: what else has changed, and how long has this been going on? Why you might feel tired Not getting enough sleep is one possible explanation, but it is far from the only one. Stress, low mood, pregnancy, menopause, recent illness and some medicines can all contribute. Persistent fatigue can also occur with conditions such as iron deficiency anaemia, diabetes, thyroid disorders or sleep apnoea. Other symptoms can provide clues. Someone with sleep apnoea might snore loudly or wake up gasping. A person with anaemia may also notice breathlessness or palpitations. These combinations can help a clinician decide what to investigate, but they cannot confirm a diagnosis on their own. When should you see a clinician? Make an appointment if you have been tired for a few weeks without a clear reason, if fatigue is affecting daily life, or if it comes with changes such as unexplained weight loss, mood changes or interrupted breathing during sleep. Before the appointment, note when the fatigue started, how you sleep, any other symptoms and any medicines or supplements you take. Depending on your history and examination, a clinician may suggest blood tests or further assessment. Seek emergency care for severe symptoms such as chest pain, severe difficulty breathing, fainting or new confusion. The takeaway Rest and a consistent sleep routine can help some people, but persistent fatigue deserves attention. You do not need to find the answer on your own before asking for help. Source: NHS: Tiredness and fatigue. Illustrative photograph: Ron Lach / Pexels.
Hair shedding or hair loss? What your hairbrush can and can’t tell you
For a small group with rectal cancer, immunotherapy changes the treatment conversation
After the smoke clears, wildfire survivors may still need lung-health follow-up
GRAYMEDY RESEARCH ANALYSIS · November 8, 2026 Before someone can weigh the benefits and burdens of research participation, they need a meaningful opportunity to consider it. A newly published national survey of U.S. women places that opportunity under scrutiny. An invitation gap Doruntina Fida, Therese A. Rajasekera, Primavera A. Spagnolo and colleagues surveyed 5,301 U.S. women aged 18–70. The peer-reviewed accepted paper appeared in Scientific Reports on November 7, 2026. The authors reported that 23% expressed definite willingness to participate and 60% answered maybe, while 11% said they had been invited and 7% had enrolled. Among respondents reporting race, the sample was predominantly White. Adjusted analyses associated lower willingness with being Black rather than White, while higher education and multimorbidity were associated with greater willingness. Respondents’ preferred information, motivations and perceived barriers also differed. These are associations within the surveyed population, rather than explanations of individual choices. Interest is not consent An expression of interest in a survey does not tell researchers whether someone would join a particular trial. A real decision depends on the intervention, uncertainty, visits, travel, childcare, costs and other personal circumstances. The maybe response is especially important: it represents a question requiring discussion rather than a commitment waiting to be activated. Graymedy’s reading is that the invitation gap deserves attention without turning willingness into a recruitment target that overrides autonomy. Improving access means giving eligible people understandable choices and enough room to decline. It does not mean assuming that everyone who is interested in research should enrol. What the design cannot resolve This was a cross-sectional online survey, not an experiment testing an invitation programme. Self-reported experience is subject to recall, and the people answering an online survey may differ from women who did not participate. The results therefore cannot establish a national causal explanation for underrepresentation. Race should not be read as a biological explanation for willingness. The study considers social and structural conditions alongside healthcare access, socioeconomic circumstances and health. A group-level result also cannot tell a clinician what an individual woman wants or why she might decline. Asking and listening remain essential. Turning a finding into a care question The authors call for evaluation of culturally responsive engagement, trust-building and approaches that reduce burden. Those are strategies to test, rather than interventions proven effective by this survey. A useful next study would measure whether changes improve informed opportunities and representation while preserving the quality of consent. At a service level, one possible audit would track eligible patients, invitations offered, invitations understood and participation decisions. Recording reasons for not being invited could reveal a different problem from recording reasons for declining. Such an audit would also need to protect privacy and avoid making research participation feel like a condition of good care. The central message is modest but consequential: low enrolment cannot automatically be equated with low interest. Research teams need to understand the route between a person’s willingness to hear more and the practical opportunity to make an informed choice. Sources and publication dates Fida et al., Scientific Reports, November 7, 2026; accepted article version Independent editorial analysis of published research; no interview or endorsement is implied. Image credit: National Cancer Institute, image 4187, circa 2006. Public domain. Original image source.
Diet during antibiotics: a transplant study puts the hospital menu under scrutiny
A clinic on wheels brings a survival signal—and a harder question about addiction care